Sarepta Therapeutics, Inc. (SRPT)
Sarepta Therapeutics, Inc. (SRPT) from its SEC filings: 2025 revenue $1.9 billion (+4% vs the year before), net margin -38%, free cash flow -$307.5 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Revenue (2025) | $1.9 billion |
| Revenue growth | +4% |
| Net income | -$713.4 million |
| Net margin | -38.3% |
| Free cash flow | -$307.5 million |
| Diluted EPS | $-7.13 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | -36% |
| Cash | $571.1 million |
| Long-term debt | $1.4 million |
| Share count, 1 year | +8% |
| Fundamentals check | Weak fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-24. Education only, not financial advice.